Central to the pathways that induce cell growth in mammals is the murine target of rapamycin (mTOR), a multi-domain, 298 kDa, evolutionarily-conserved Ser/Thr kinase that is inhibited by the drug rapamycin (Schmelzle and Hall, 2000) . mTOR exerts its effects by phosphorylating eukaryotic initiation factor 4E binding protein 1 (4EBP1), which inhibits 5′-cap-dependent mRNA translation (the majority of cellular translation) by binding and inactivating eIF4E. Phosphorylation of 4EBP1 releases eIF4E, allowing initiation of translation (Gingras et al., 2004) . In addition to 4EBP1, mTOR also regulates translation via S6 kinase (S6K, formerly known as p70 s6K ). This Ser/Thr kinase phosphorylates the ribosomal S6 protein, facilitating recruitment and translation of a specific mRNA subset that contains a 5′ polypyrimidine tract (5′-TOP) (Dufner and Thomas, 1999) . 5′-TOP transcripts encode several ribosomal proteins and translation elongation factors. By acting on S6K, mTOR facilitates ribosome biogenesis and translation elongation (Gingras et al., 2004; Dufner and Thomas, 1999) . To recognize 4EBP1 and S6K, mTOR must associate with a protein adaptor termed Raptor (for regulatory associated protein of mTOR). mTOR is found in a highly conserved complex that includes Raptor (Kim et al., 2002; Hara et al., 2002 ) and a protein of unknown function called mLST8 (Chen and Kaiser, 2003) . mTOR activation depends on several inputs, including nutrients (amino acids), energy (ATP) and growth factors (Schmelzle and Hall, 2000) . Both ATP and amino acid deprivation result in mTOR inactivation, even in the presence of growth factors such as insulin (Schmelzle and Hall, 2000, Gingras et al., 2004; Dufner and Thomas, 1999) . The mechanism by which amino acids and ATP activate mTOR is not completely clear. Nonetheless, under energy starvation conditions, the AMP-activated protein kinase (AMPK) phosphorylates and activates tuberous sclerosis protein 2 (TSC2, also termed tuberin) (Inoki et al., 2003) , which inhibits mTOR in combination with TSC1 (hamartin) (Inoki et al., 2003; Potter et al., 2003; Gao et al., 2002) . Amino acid deprivation has also been shown to regulate mTOR via the TSC complex (Gao et al., 2002) . Restoration of ATP or amino acids induces mTOR activation, which is further increased by growth factor addition. Growth factors regulate mTOR via phosphoinositide 3-kinase (PI3K), protein kinase B (PKB/Akt) and TSC.
PI3K catalyzes generation of 3-polyphosphoinositides, whose levels are negatively controlled by the tumor suppressor PTEN (phosphatase and tensin homolog on chromosome 10). PI3K is a crucial mediator of cell growth. In fact, the transient kinetics of PI3K activation following growth factor receptor stimulation determine the transient induction of growth signaling pathways such as S6K (Alvarez et al., 2003) . The PI3K p85 regulatory subunit associates with mTOR, and this complex is required for mTORmediated S6K activation (GonzalezGarcia et al., 2002) . PI3K also mediates S6K activation via its effector, PDK1 (3-phosphoinositide-dependent protein kinase) (Romanelli et al., 2002) , and regulates 5′-TOP mRNA translation independently of S6K (Stolovich et al., 2002) . In addition, active PI3K neutralizes the action of the TSC complex (Inoki et al., 2003; Potter et al., 2003; Gao et al., 2002) . It was recently reported that the small GTPase Rheb (Ras homologue enriched in brain) is required for mTOR activation. Rheb acts as a bridge between TOR and TSC, because it is regulated directly by the TSC2 GAP activity (Manning and Cantley, 2003) . To release mTOR from TSC inhibitory action, growth factors such as insulin or serum activate PI3K and its effector, PKB, which in turn phosphorylates and inactivates TSC2 (Inoki et al., 2002) . Nutrients and energy levels also regulate TSC complex activity (see above). Further studies are needed to clarify the crosstalk required to bring together ATP, nutrient and mitogen signals for mTOR activation.
